Status:
COMPLETED
Use of Real-time Continuous Glucose Monitoring System in Patients With Type 1 Diabetes Mellitus
Lead Sponsor:
Norwegian University of Science and Technology
Collaborating Sponsors:
Norwegian Diabetes Association
Conditions:
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether a real-time continuous glucose monitoring system is able to improve HbA1c in patients suffering from type 1 diabetes compared to conventional finger p...
Eligibility Criteria
Inclusion
- Diabetes Mellitus, Type 1 \> 3 years.
- For practical reasons patients should live in Trondheim, Malvik, Melhus or Klæbu.
- Level of HbA1c (measured by DCA 2000) between 7 and 10 % and/or experience blood glucose \< 3 mmol/L (verified by finger-prick measurement) at least once a week and/or at least one episode with serious hypoglycemia the previous half a year.(Defined as need of help from others)
- Only patients who use insulin pumps or multi-injection regime (=3 daily injections with short term acting insulin or insulin analogue + at lest one daily injection with NPH-insulin or long term acting insulin analogue.
Exclusion
- Patients with other diseases such as untreated hypothyroidism, adrenal gland failure, celiac disease, renal failure, unstable coronary heart disease, serious psychiatric disorder, or mental retardation.
- Patients who are not able to learn how to use the continuous glucose monitoring system given a reasonable amount of effort.
- Patients who are not able to do the glucose measurements, insulin dose change and diary notes which the study demands.
- Unsuited for participating from any other cause.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00824148
Start Date
January 1 2009
End Date
September 1 2009
Last Update
February 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, St. Olavs Hospital
Trondheim, Norway, N-7006